Weekly Roundup: January 17-21

POLL: Are Your Patients Turning to CBD Products to Treat Skin Conditions?

What's Happening in Infectious Disease?

Ted Rosen, MD, explains the top points of his presentation, "What's Hot and New in Infectious Disease?" from the 2022 Winter Clinical Dermatology Conference.

Misconceptions, Pipeline, and Prevention of ID

What new treatments are coming to infectious disease? How can they be prevented and what misconceptions are affecting treatment? Learn about this and more in this video with Ted Rosen, MD.

Top Tips for the Practice

Sunscreen advice, recruiting during the “Great Recession”, and tips for the office led the busy agenda at Winter Clinical Dermatology Conference this weekend.

Biologics Offer Range of Options for Dermatologists Looking to Treat Patients

Studies offer positive outcomes for patients with conditions like hidradenitis suppurativa or psoriasis.

Bimekizumab’s Potential in Moderate-to-Severe Plaque Psoriasis

A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.

Plaque Psoriasis: Biologic Therapy Toxicity Profiles

A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.

Prevention Is Paramount When Addressing Infectious Diseases

As skin manifestations are commonly the first thing spotted with infectious disease, dermatologists are in a great position to counsel patients about prevention.

A Good Resource for Molluscum Contagiosum Is Hard to Find

More trustworthy sources of information, and data, are needed.

FDA Approves Upadacitinib for Moderate to Severe AD

AbbVie announces the approval after 3 studies show the efficacy and safety of upadacitinib using mono- and combination therapy.

Risk of Systemic Absorption with JAK Inhibitors

Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.

Poster Aims to Show Improvement in Resident Billing

Resident billing can have huge financial implications on academic institutions. A poster from the Icahn School of Medicine at Mount Sinai aimed to assess new medical coding lectures and a modified note template at Winter Clinical Dermatology Conference.

Answers to Your Patients' Questions on Skin Care

Targeting skin care regimens to the individual patient is most likely to yield compliance to a recommended routine.

Abrocitinib FDA Approved for AD

The FDA has approved abrocitinib for adult patients with moderate to severe AD.

Top Priorities for the AAD: 2022

AAD vice president challenges dermatologists to advocate for their patients and themselves.

Diagnosing Skin Issues Pose Challenges in SOC

One of the key differences between diagnosing AD in patients with skin of color compared to White skin is erythema.

Expert Pearls for Treating Rosacea Patients

Treating these patients can be a challenge, but it can also be ‘as easy as pie’ if you follow these tips.

FDA Approval Gives Dermatologists New Option for Uncontrolled AD

The FDA approved the topical JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis in September 2021.

The Future of Dermatology CRO discussed

Vial announced an advisory board to discuss dermatology CROs at the 2022 Winter Clinical Dermatology Conference.

New Tapinarof Data Released

Dermavant had patient satisfaction data from the PSOARING 3 long term extension trial presented at the 2022 Winter Clinical Dermatology Conference.

Treating Atopic Dermatitis with Ruxolitinib

Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.

Pointers with Dr Portela: Urine for Skin Care?

In this week’s Pointers with Dr Portela, the 208SkinDoc dives into a social media video that shows someone advocating for urine for hair, skin, and overall body care. See what he has to say about this.

Psoriasis Treatment Response: It’s Relation to Comorbid Obesity and Diabetes

A study published in the Journal of the American Academy of Dermatology did a prospective analysis on psoriasis biologic treatment response related to comorbid obesity and a history of diabetes.

Research Letter: Psoriasis and Melanoma Risk

A research letter published by the Journal of the American Academy of Dermatology dove into the question of how psoriasis may increase the overall risk of cutaneous malignant melanoma in patients.

Dermatology Times® EAB Member to be Keynote Speaker at Medical Spa Show 2022

Will Kirby, DO, FAOCD, board-certified dermatologist, chief medical officer of LaserAway, and Dermatology Times® editorial board member, will be speaking at the Medical Spa Show, presented by the American Med Spa Association.

EHR notes may enhance and prolong racial bias: study

Clinicians need to avoid negative terms in describing patients.

CDC updates mask guidance

With increased infectivity of Omicron, the Centers for Control and Prevention (CDC) has updated the guidance on the best mask types to use.